Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Gains from Investment Securities: 2018-2024

Historic Gains from Investment Securities for Kiniksa Pharmaceuticals International (KNSA) over the last 7 years, with Dec 2024 value amounting to $9.7 million.

  • Kiniksa Pharmaceuticals International's Gains from Investment Securities rose 37930.00% to $3.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.3 million, marking a year-over-year increase of 58.26%. This contributed to the annual value of $9.7 million for FY2024, which is 16.07% down from last year.
  • Latest data reveals that Kiniksa Pharmaceuticals International reported Gains from Investment Securities of $9.7 million as of FY2024, which was down 16.07% from $11.6 million recorded in FY2023.
  • Kiniksa Pharmaceuticals International's Gains from Investment Securities' 5-year high stood at $18.3 million during FY2020, with a 5-year trough of $9.2 million in FY2021.
  • Moreover, its 3-year median value for Gains from Investment Securities was $10.1 million (2022), whereas its average is $10.5 million.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first skyrocketed by 928.77% in 2020, then slumped by 49.50% in 2021.
  • Yearly analysis of 5 years shows Kiniksa Pharmaceuticals International's Gains from Investment Securities stood at $18.3 million in 2020, then plummeted by 49.50% to $9.2 million in 2021, then rose by 9.95% to $10.1 million in 2022, then climbed by 14.34% to $11.6 million in 2023, then decreased by 16.07% to $9.7 million in 2024.